Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
about
New atypical antipsychotics for schizophrenia: iloperidoneExtrapyramidal side-effects of antipsychotics in a randomised trial.Tardive dyskinesia: therapeutic options for an increasingly common disorder.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IIA case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up.Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis.No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia PatientsIncidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyEthical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.Tardive dyskinesia: treatment with aripiprazole.Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.An update on tardive dyskinesia: from phenomenology to treatmentGenetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.The role of pharmacogenetics in treating central nervous system disorders.Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.Aripiprazole (abilify) and tardive dyskinesia.Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.Tardive Blepharospasm and Meige Syndrome during Treatment with Quetiapine and Olanzapine.Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Treating psychosis in movement disorder patients: a review.Psychotropic drugs and bruxism.Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?Unusual morphology of scapulae: incidence and dimensions of ossified ligaments and supraspinous bony tunnels for clinical consideration.Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus.The catechol-O-methyl-transferase gene in tardive dyskinesia.There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients.Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia.Tardive dyskinesia and other movement disorders secondary to aripiprazole.Use of aripiprazole in tardive dyskinesia: an open label study of six cases.Metoclopramide, an increasingly recognized cause of tardive dyskinesia.Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia.
P2860
Q30482195-1ADA2A99-A10B-4D92-80BA-6F494DC06F08Q30492645-CA05E35E-B79E-4D78-8847-E305EB2EBEC6Q30566749-9562675F-2EBB-4B82-B8EE-E38BA4F595C7Q33612521-98C4FCEC-0629-4CE8-9DB7-EE1F5DFE54A0Q33618959-B004825A-37B0-4EFA-B3E9-0B5971C98F40Q34447349-EF4DE489-301C-47BD-B552-349E9422D9F4Q34653803-AD5EFCE1-CF52-43AD-BE37-6C73B4B42415Q34660856-B5295D9B-B743-40CF-8383-9468CC7F9C6EQ34734254-0AAC4204-28D4-4AC5-9E64-18CC09CC0338Q34811987-0F85AB6D-7105-493C-9F49-0DDF73A3485EQ35030003-91055D3A-753E-4879-9C28-5D93D1FF799FQ35693061-E6F6A08F-AC53-4BD2-9D04-2EF5F085C6E7Q36599203-6D02B7BF-84B1-4C9C-82A0-D03242C4C24AQ36727009-3BC4EC38-1702-4B74-B5CC-74A681764DFCQ36816763-80EA804A-97E9-443A-96A5-B252D9F34B5BQ36965451-D0CA09F8-F85B-4C0B-AA7B-3D86A7297277Q37006021-493A4D92-185C-4822-B045-DEC62DA5CB4DQ37264543-6711F50A-4BA6-459F-8751-686F1568AEA2Q37292132-601BEDB3-183D-47B9-9791-86EBDCC79FC7Q37302639-CCDC0A3D-9742-4617-92A7-94E48CB131DEQ37313562-89996DB3-4606-44C3-82D2-4DD8D22EE6F2Q37460501-E8F2DF62-DC29-4BE3-BE11-1C7277AA2823Q37704065-F4218E57-6850-44EC-A5AC-57397D7A2CCDQ37868985-6AE24C71-4D4A-4CCA-98CA-B49408FCF919Q37952823-12241787-E4F2-490F-A153-FD08D75CD902Q38015698-A3C1E0CC-F32E-4319-9026-4E5F4390F363Q38032249-678E02CE-2641-48CF-9F4E-B2853AD3BDEBQ38213306-F17B73EB-FF3F-4058-A837-E80FCF57788FQ38246656-B16FBE02-1D5E-4362-9193-07CB1DD77156Q38672722-4B7466D8-6287-464A-BC01-8DB962D2F7A4Q39287194-3C04F269-5D60-48A6-B6DD-FD1DDDEEF842Q40036273-E42E4C3A-8D1D-4190-826E-A5BA4BE0C994Q42828130-F8B7BB40-6F37-4BCF-9E55-0BA67CC7D979Q43002336-6242DC28-4426-411B-9470-33AA9B913DDFQ44820338-D4207C74-DCF2-4F7B-9772-F56DACB38EF6Q45185178-D4CB21D1-5C82-4CD5-B856-D2BC77F6B158Q45282349-9C83E770-BFE2-48B4-8EAF-D1DD48826AC4Q45984822-003D35E0-038D-4946-852F-8C4E6AC43E43Q46789002-D096331F-8C4E-4A43-8A19-7461E15C327AQ50616840-3AAF68EA-A369-4BFC-BEA5-37E490AE4877
P2860
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@ast
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@en
type
label
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@ast
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@en
prefLabel
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@ast
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@en
P356
P1433
P1476
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
@en
P2093
Daniel Tarsy
Ross J Baldessarini
P304
P356
10.1002/MDS.20823
P407
P577
2006-05-01T00:00:00Z